FACULTY
Shannon H. Kasperbauer, MD
Associate Professor of Medicine
Department of Medicine
Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, CO
Charles L. Daley, MD
Chief, Division of Mycobacterial and Respiratory Infections
National Jewish Health
Professor of Medicine
National Jewish Health and University of Colorado
Denver, CO
PROGRAM OVERVIEW
This enduring activity is designed aims to help HCPs reduce time to diagnosis in patients with suspected NTM-LD, individualize treatment selection for patients with NTM-LD in frontline and refractory settings based on clinical guidelines and patient characteristics, evaluate the role of amikacin liposome inhalation suspension (ALIS) in the treatment of patients with NTM-LD, and optimize strategies to avoid and manage the adverse effects of antibiotic therapy inpatients with NTM-LD and facilitate the completion of therapy.
TARGET AUDIENCE
This activity is designed to meet the educational needs of pulmonology professionals (including MDs, DOs, NPs, PAs and pharmacists) who have a role in the diagnosis and treatment of patients with NTM-LD.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Assess best practices in reducing time to diagnosis of NTM-LD in patients with nonspecific symptoms
- Explain best practices for treatment selection in NTM-LD, both in the frontline and refractory setting, as informed by clinical guidelines
- Interpret data from clinical trials concerning the role of amikacin liposome inhalation suspension (ALIS) in the treatment of patients with NTM-LD
- Summarize strategies for avoidance of adverse events associated with NTM-LD therapies and strategies for improving patient and clinician communication to optimize therapeutic persistence
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
Dr. Kasperbauer is a speaker for Insmed and Paratek, and serves as a consultant for AN2 Therapeutics, Insmed and Paratek.
Dr. Daley is a consultant for AN2 Therapeutics, AstraZeneca, Cepheid, Genentech, Hyfe Al, Insmed, Paratek, Pfizer, Spero Therapeutics and Zambon. He disclosures contracted research with AN2 Therapeutics, Beyond Air, Bugworks, Insmed, Juvabis, and Paratek. He serves on the Data Monitoring Committee for Gates Foundation, Lilly and Otsuka.
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Debra Gordon, MS, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Felecia Beachum, Program Manager for Med Learning Group, has nothing to disclose.
- Naomi De Brito, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME information and faculty disclosures
- Participate in the enduring activity.
- Submit the evaluation form to the Med Learning Group
You will receive your certification as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For questions, please contact Med Learning Group at [email protected].
Contact this provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: June 09, 2023
EXPIRATION DATE: June 09, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.